The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.
It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And there are biologics—IL-13 and IL-31 inhibitors—and JAK inhibitors in the pipeline showing promise.
From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis.
2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.
On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.
New Data Supports the Safety and Efficacy of Dupixent in Adults and Children with AD
New Dermatology Atlas to Highlight and Compare Features of Common Dermatologic Conditions in Different Skin Types
Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis
New York’s Mount Sinai Health System Names New Chair of Dermatology and New Dean For Clinical Therapeutics
DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates
And the Winner Is...Dr. Junko Takeshita of University of Pennsylvania Wins 2020 Childhood Eczema Challenge Grant
Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis
Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasis
Mount Sinai Researcher Receives NIH Grant to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19
Ask Dr. Friedman
A healthy microbiome is a hallmark of healthy skin, while dysbiosis is implicated in various dermatologic diseases. Dr. Friedman explains how this...
Adam Friedman, MD, FAAD